AMPCO PITTSBURGH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AMPCO PITTSBURGH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $434.17M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $418.31M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $422.34M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $390.19M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $344.92M | Mar 21, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.28M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $402.80M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $415.32M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $380.26M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $335.08M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $328.54M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $397.90M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $419.43M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $385.16M | Mar 18, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.75M | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | $16.59M | Mar 16, 2018 |
| FY2017 | Jun 30, 2017 | $18.53M | Mar 16, 2018 |
| FY2017 | Mar 31, 2017 | $18.85M | Mar 16, 2018 |
| FY2016 | Dec 31, 2016 | $11.45M | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | $15.59M | Mar 16, 2017 |
| FY2016 | Jun 30, 2016 | $15.85M | Mar 16, 2017 |
| FY2016 | Mar 31, 2016 | $12.47M | Mar 16, 2017 |
| FY2015 | Dec 31, 2015 | $8.13M | Mar 15, 2016 |
| FY2015 | Sep 30, 2015 | $9.44M | Mar 15, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.07M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $438.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($39.93M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $3.42M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($3.86M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $7.97M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($20.99M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($69.34M) | Mar 16, 2020 |
| FY2017 | Dec 31, 2017 | ($3.19M) | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | ($2.20M) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.48M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $12.17M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($34.57M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $2.78M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($4.78M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $6.45M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($10.91M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($44.89M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($13.77M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($54.53M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $494.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $441.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $662.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.02M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.23M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.05M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.52M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.66M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $3.39M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $2.72M | Mar 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.13M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $54.88M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $50.88M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $43.53M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $46.00M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $45.54M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $53.64M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $58.07M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $60.16M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $58.18M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $18.03M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($3.69M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($27.21M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($15.87M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $33.64M | Mar 17, 2022 |
| FY2014 | Dec 31, 2014 | $19.98M | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $37.77M | Mar 16, 2015 |
| FY2014 | Dec 31, 2012 | $25.44M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $22.29M | Mar 17, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.41M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $12.19M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $20.45M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $16.69M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $15.24M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $8.47M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $10.96M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $9.72M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $13.01M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $10.57M | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $495.36M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $530.90M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $565.65M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $502.77M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $505.96M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $463.21M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $506.56M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $571.12M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $565.60M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $565.89M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.39M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $459.81M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $494.08M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $389.38M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $393.83M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $378.21M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $450.94M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $478.15M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $403.84M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $416.06M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.64M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $58.88M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $60.94M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $104.33M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $102.90M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $76.56M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $48.90M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $87.60M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $158.94M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $147.92M | Mar 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($138.63M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($72.56M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($73.00M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($32.32M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($35.74M) | Mar 21, 2023 |
| FY2022 | Jan 1, 2021 | $11.49M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($43.37M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($51.34M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($30.36M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $38.35M | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.70M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $15.43M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $7.29M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $8.74M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $10.34M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $16.84M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $6.96M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $19.71M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $18.66M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $38.58M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | (5) | Mar 16, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 16, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | (5) | Mar 16, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.24M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 19.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 19.73M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 19.40M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 19.18M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 18.31M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 12.65M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 12.50M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 12.36M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 12.27M | Mar 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $35.0K | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $2.24M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.21M | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $7.51M | Mar 16, 2018 |
| FY2016 | Dec 31, 2014 | $7.49M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $7.46M | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $7.44M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $7.43M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $7.38M | Mar 15, 2013 |
| FY2011 | Dec 31, 2009 | $7.34M | Mar 15, 2012 |